mouse CD19/APC-Cy7

Applications

Reactivity

Mouse

Overview
Catalog #	bsm-30156A-APC-CY7
Product Name	mouse CD19/APC-Cy7
Applications	FCM
Reactivity	Mouse
Specifications
Conjugation	Unconjugated
Host	Rat
Clonality	Monoclonal
Clone #	5C7
Isotype	IgG2a/Kappa
Concentration	n/a
Purification	Affinity purified by Protein G
Storage Buffer	0.01M PBS, 0.5%BSA, 0.03% Proclin300
Storage Condition	Store at 2-8℃. Protect from light. Avoid freezing.
Target
Gene ID	12478
Swiss Prot	P25918
Synonyms	Antibody deficiency due to defect in CD19, included; AW495831; B lymphocyte antigen CD19; B lymphocyte surface antigen B4; B4; CD 19; CD19 antigen; CD19 molecule; Cd19 protein; Differentiation Antigen CD19; Leu 12; Leu12; Lymphocyte Surface Antigen; MGC109570; MGC12802; T-cell surface antigen Leu-12; CD19_MOUSE.
Background	This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]
Application Dilution
FCM	1:20-100